The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy
Open accessAbstract
Autoantibodies specific for idiopathic inflammatory myopathy (myositis-specific autoantibodies (MSAs)) are clinically useful biomarkers to help the diagnosis of polymyositis/dermatomyositis (PM/DM). Many of these are also associated with a unique clinical subset of PM/DM, making them useful in predicting and monitoring certain clinical manifestations. Classic MSAs known for over 30 years include antibodies to Jo-1 (histidyl transfer RNA (tRNA) synthetase) and other aminoacyl tRNA synthetases (ARS), anti-Mi-2, and anti-signal recognition particle (SRP). Anti-Jo-1 is the first autoantibodies to ARS detected in 15–25 % of patients. In addition to anti-Jo-1, antibodies to seven other aminoacyl tRNA synthetases (ARS) have been reported with prevalence, usually 1–5 % or lower. Patients with any anti-ARS antibodies are associated with anti-synthetase syndrome characterized by myositis, interstitial lung disease (ILD), arthritis, Raynaud’s phenomenon, and others. Several recent studies suggested heterogeneity in clinical features among different anti-ARS antibody-positive patients and anti-ARS may also be found in idiopathic ILD without myositis. Anti-Mi-2 is a classic marker for DM and associated with good response to steroid treatment and good prognosis. Anti-SRP is specific for PM and associated with treatment-resistant myopathy histologically characterized as necrotizing myopathy. In addition to classic MSAs, several new autoantibodies with strong clinical significance have been described in DM. Antibodies to transcription intermediary factor 1γ/α (TIF1γ/α, p155/140) are frequently found in DM associated with malignancy while anti-melanoma differentiation-associated gene 5 (MDA5; CADM140) are associated with clinically amyopathic DM (CADM) complicated by rapidly progressive ILD. Also, anti-MJ/nuclear matrix protein 2 (NXP-2) and anti-small ubiquitin-like modifier-1 (SUMO-1) activating enzyme (SAE) are recognized as new DM-specific autoantibodies. Addition of these new antibodies to clinical practice in the future will help in making earlier and more accurate diagnoses and better management for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021933 · Cited by 2,578
Love, L. A., Leff, R. L., Fraser, D. D., Targoff, I. N., Dalakas, M., Plotz, P. H., & Miller, F. W. (1991) · Medicine · doi:10.1097/00005792-199111000-00002 · Cited by 969
Zhang, Y., LeRoy, G., Seelig, H.-P., Lane, W. S., & Reinberg, D. (1998) · Cell · doi:10.1016/s0092-8674(00)81758-4 · Cited by 816
Sato, S., Hirakata, M., Kuwana, M., Suwa, A., Inada, S., Mimori, T., Nishikawa, T., Oddis, C. V., & Ikeda, Y. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21023 · Cited by 747
Sato, S., Hoshino, K., Satoh, T., Fujita, T., Kawakami, Y., Fujita, T., & Kuwana, M. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24621 · Cited by 604
Fiorentino, D., Chung, L., Zwerner, J., Rosen, A., & Casciola-Rosen, L. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.09.016 · Cited by 554
Gerami, P., Schope, J. M., McDonald, L., Walling, H. W., & Sontheimer, R. D. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.10.041 · Cited by 455
Prevalence and sociodemographic correlates of antinuclear antibodies in the United States
Satoh, M., Chan, E. K. L., Ho, L. A., Rose, K. M., Parks, C. G., Cohn, R. D., Jusko, T. A., Walker, N. J., Germolec, D. R., Whitt, I. Z., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34380 · Cited by 448
Self-citationAssociation of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer
Joseph, C. G., Darrah, E., Shah, A. A., Skora, A. D., Casciola-Rosen, L. A., Wigley, F. M., Boin, F., Fava, A., Thoburn, C., Kinde, I., et al. (2014) · Science · doi:10.1126/science.1246886 · Cited by 436
Autoantibody profiles in the sera of European patients with myositis
Brouwer, R., Hengstman, G. J. D., Egberts, W. V., Ehrfeld, H., Bozic, B., Ghirardello, A., Grøndal, G., Hietarinta, M., Isenberg, D., Kalden, J. R., et al. (2001) · Annals of the Rheumatic Diseases · doi:10.1136/ard.60.2.116 · Cited by 409
Cited by
Damoiseaux, J., Andrade, L. E. C., Carballo, O. G., Conrad, K., Francescantonio, P. L. C., Fritzler, M. J., Garcia de la Torre, I., Herold, M., Klotz, W., Cruvinel, W. D. M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-214436 · Cited by 378
Self-citationXist ribonucleoproteins promote female sex-biased autoimmunity
Dou, D. R., Zhao, Y., Belk, J. A., Zhao, Y., Casey, K. M., Chen, D. C., Li, R., Yu, B., Srinivasan, S., Abe, B. T., et al. (2024) · Cell · doi:10.1016/j.cell.2023.12.037 · Cited by 233
Krock, E., Morado-Urbina, C. E., Menezes, J., Hunt, M. A., Sandström, A., Kadetoff, D., Tour, J., Verma, V., Kultima, K., Haglund, L., et al. (2023) · Pain · doi:10.1097/j.pain.0000000000002881 · Cited by 84
Metadata
- Authors
- Satoh, M., Tanaka, S., Ceribelli, A., Calise, S. J., & Chan, E. K. L.
- Venue
- Clinical Reviews in Allergy & Immunology
- Published
- 2015-09-30
- Volume
- 52
- Issue
- 1
- Pages
- 1-19
- ISSN
- 1080-0549 (ISSN-L)
- 1559-0267
- OpenAlex
- W2109091387
- Cited by
- 420
- References
- 60
- FWCI
- 15.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. https://app.cochat.ai/papers/10.1007/s12016-015-8510-y
- The paper
- Satoh, M., Tanaka, S., Ceribelli, A., Calise, S. J., & Chan, E. K. L. (2017). A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. Clinical Reviews in Allergy & Immunology. https://doi.org/10.1007/s12016-015-8510-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
